Cargando…
Molecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives
Drug-induced liver injury (DILI) is one among the common adverse drug reactions and the leading causes of drug development attritions, black box warnings, and post-marketing withdrawals. Despite having relatively low clinical incidence, its potentially severe adverse events should be considered in t...
Autores principales: | Fu, Siyu, Wu, Dongbo, Jiang, Wei, Li, Juan, Long, Jiang, Jia, Chengyao, Zhou, Taoyou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7002317/ https://www.ncbi.nlm.nih.gov/pubmed/32082163 http://dx.doi.org/10.3389/fphar.2019.01667 |
Ejemplares similares
-
Chronic Drug-Induced Liver Injury: Updates and Future Challenges
por: Wang, Qiaoling, et al.
Publicado: (2021) -
Drug Development for the Irritable Bowel Syndrome: Current Challenges and Future Perspectives
por: De Ponti, Fabrizio
Publicado: (2013) -
Drug-Induced Liver Injury: Biomarkers, Requirements, Candidates, and Validation
por: Meunier, Lucy, et al.
Publicado: (2019) -
Herbal Therapy for the Treatment of Acetaminophen-Associated Liver Injury: Recent Advances and Future Perspectives
por: Chang, Ling, et al.
Publicado: (2020) -
The Immunological Mechanisms and Immune-Based Biomarkers of Drug-Induced Liver Injury
por: Liu, Wenhui, et al.
Publicado: (2021)